Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Diabetic Macular Edema & Treatment Strategies
Diabetic macular edema (DME) is the leading cause of blindness in the diabetic population. Although its prevalence varies, the Diabetes Control and Complications Trial (DCCT) reported that 27% of type 1 diabetes (DM1) patients developed macular edema within nine years…
Advancements in Treatment of Open-Angle Glaucoma
Most people who have open-angle glaucoma feel fine and do not notice a change in their vision at first because the initial loss of vision is of side or peripheral vision, and the visual acuity or sharpness of vision is…
Latest Medications For Dry Eye Disease Treatment
Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. The chance of experiencing dry eye increases with age, affecting approximately…
AGTC-501 Offers Vision Gains for X-Linked RP
Inherited retinal diseases (IRDs), also referred to as inherited retinal dystrophies, are a clinically and genetically heterogeneous group of neurodegenerative disorders, primarily involving photoreceptors, retinal pigment epithelium (RPE), and/or the choroid. Taken as a whole, IRDs have an estimated global…
FDA Approves Cyclosporine Eye Drops
Verkazia 0.1%) eye drops containing cyclosporine have been authorized by the US Food and Drug Administration (FDA) for the treatment of vernal keratoconjunctivitis (VKC) in both adult and juvenile populations. The surface of the eyes in patients with the uncommon,…
Improved Vision Through A Supplement
Mexican marigold also known as cempasúchil, or Aztec marigold is a native flower to México and was first used by the Aztecs and is used in the Mexican holiday “Dia de los muertos” or day of the dead. The Aztecs used it…
Oral Azithromycin vs Doxycycline for MGD
A study published online in JAMA Ophthalmology found that treatment of severe meibomian gland dysfunction (MGD) with three weeks of oral azithromycin is equivalent to six weeks of doxycycline. The study was conducted by Phit Upaphong, M.D., from Chiang Mai…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…